Platform Science Team News Contact

Disappears when not in use.

The Alsteni System is the first invisible, removable feeding tube — an intraorally-anchored alternative to nasogastric and PEG tubes. No tube on the face. No surgical hole. Nothing visible at all.

TPA Molar anchor Jejunum ↓
$0B
global enteral nutrition market

A market that has seen almost no innovation in decades. Products work medically — nutrients go in, patients survive — so manufacturers have had little incentive to improve the experience. But surviving is not the same as living.

Grand View Research, Global Enteral Feeding Devices Market, 2024

0K+
Americans depend on enteral feeding

A population growing every year as cancer survival improves and the population ages. These patients need nutrition delivered past the stomach — but current options force a choice between visibility and health.

ASPEN Clinical Guidelines, 2024

0M
Americans with Type 2 diabetes

42 million Americans live with Type 2 diabetes — a $400B annual burden on the U.S. healthcare system. The American Diabetes Association now endorses Total Dietary Replacement (TDR) as a management strategy. Published TDR trials have demonstrated remission rates as high as 87% (DiRECT, Lean et al. 2018). These protocols require precise enteral nutrition delivery — the core capability the Alsteni System is being developed to provide.

ADA Standards of Care, 2024; Taylor et al., DiRECT Trial, The Lancet, 2018

Supported by USC Techstars '25 · NSF I‑Corps · Coulter Foundation Advisors from Mayo Clinic · Columbia · USC Keck · U. Adelaide Supported by USC Techstars '25 · NSF I‑Corps · Coulter Foundation Advisors from Mayo Clinic · Columbia · USC Keck · U. Adelaide
550K+
Americans depend on feeding tubes. The tubes work. The experience doesn't.

Patients who need enteral nutrition skip family gatherings, avoid photographs, eat alone — because the sight of tube feeding makes others uncomfortable. Body image concerns and social isolation drive many to refuse feeding tubes entirely. Today's options force an impossible choice: a nasogastric tube taped across your face that brands you as sick, or a PEG tube — a surgical hole in your abdomen with lifelong wound care. There has been no meaningful alternative — until now.

Today's standard
Nasogastric Tube
  • Taped across the face — every person you meet knows you're sick
  • Dislodges regularly, requiring painful reinsertion
  • Patients stop going out, skip family events, eat alone
or
Today's standard
Gastrostomy (PEG) Tube
  • A permanent hole in the abdomen — even if the condition resolves
  • Daily wound care, ongoing infection risk at the stoma site
  • Irreversible body modification that leaves permanent scarring
How It Works

Three steps. Then it vanishes.

A short dental visit. A simple placement by your doctor. Then nothing visible — anywhere. The Alsteni System is the first feeding platform that disappears completely between uses.

1

A 30-minute visit

A general dentist places a small, permanent anchor using the same orthodontic materials found in millions of braces. It's completely invisible from the moment it's placed.

Routine dental visit · No surgery · No sedation
2

Placed by your doctor

A physician places a thin feeding tube into position. A proprietary connector locks it in place during use.

Physician-placed · Replaced monthly
3

Forget it's there

Between feedings, the tube retracts entirely inside the mouth. Nothing on the face. Nothing on the neck. Nothing on the body. No one knows.

Fully retractable · Completely invisible

Two products. One system.

The same invisible anchor serves patients who can't eat — and patients who eat too much. One platform. Two massive markets.

Alsteni Nourish

For patients who can't eat

The first invisible, fully removable feeding tube. Replaces nasogastric and PEG tubes for patients with cancer, neurological conditions, and critical illness — without surgery, facial tape, or visible hardware.

$12.1B
Global enteral nutrition market
550K+
U.S. tube-fed patients annually
Alsteni Reset

For patients who eat too much

Delivers nutrients directly to the jejunum — a location shown in published research to stimulate natural GLP-1 and satiety hormone production. No injections. No synthetic drugs. A device-based approach to metabolic therapy.

Potential future indication. Not part of the current FDA submission.
$150B+
Global weight management market
50%+
GLP-1 patients quit within a year

Same anchor. Same tube. Same platform. Alsteni Nourish launches first as a 510(k) enteral feeding device, then expands into metabolic therapy with Alsteni Reset — leveraging the same core technology to address a second, larger market.

Built on data. Not promises.

Published, peer-reviewed results from our Free2Go feasibility study — the first human trial of an intraorally-anchored feeding system.

334
Total tube-days
0
Serious adverse events
4.9%
Observed avg. weight change
10.2%
Best responder weight change

The first system patients actually tolerate

Sixteen patients enrolled. Six completed the full study protocol. Over 334 cumulative tube-days, there were zero serious adverse events — a safety profile that challenges every existing enteral feeding alternative.

Participants ate whatever they wanted with no caloric restrictions. Despite this, they averaged 4.9% total body weight loss (SD 3.4%), with the best responder losing 10.2%. The proposed mechanism: published research has shown that jejunal nutrient delivery stimulates natural GLP-1 and satiety hormone production.

Beale et al., Nutrition & Diabetes, 2020 (PMID: 32555148)
Safety
Zero serious adverse events across all patients and all tube-days. No dislodgements requiring emergency intervention.
Tolerability
Ad libitum eating — participants ate freely with no caloric restrictions or dietary protocol. Weight loss was an observed secondary finding in the feasibility study.
Next: OASIS-90
~25 patients, 60–90 days. Safety and tolerability study in protocol development with Creighton University and partner sites.

Built by operators. Not spectators.

A team with 100+ years of combined medical device experience, 42 issued patents, and over $1 billion in commercialized revenue.

Elizabeth Beale, MD
CEO & Lead Inventor
Board-certified endocrinologist. 30+ years clinical experience. USC Keck Associate Professor. Inventor of the Alsteni System and principal investigator of the Free2Go trial.
Nicholas Demetriades
Co-Founder & CMO
USC Techstars 2025. Leads fundraising, commercial strategy, and investor relations. Directs AI-augmented operations replacing 5–10 traditional hires for capital efficiency.
Arieh Halpern, MS
COO
25+ years medical device commercialization. Former Medtronic, Boston Scientific. $1B+ in revenue generated. Expert in scaling early-stage devices through regulatory and commercial launch.
Todd Oda, BS
CTO
42 issued patents. 35 years medical device development. Designed Orm Damon System ($150M+ revenue) and InBrace Gen 2. Leads product engineering and next-gen system design.
Advisory Network
Dr. Dror Dicker
Free2Go PI · Rabin Medical Center, Israel
Dr. John Anwar
OASIS-90 Lead · Creighton University
Kwame Ulmer
Former FDA Reviewer · Regulatory Strategy
Dr. Demetrios Demetriades
USC Division of Trauma Surgery
Dr. David Seres
Columbia University · ASPEN Board
John Tong, MBA
Co-founder InBrace · Raised $173–219M

What's happening

2025 USC Techstars Completed
2025 FDA Pre-Submission Filed
2025 Patent US 10,744,070 B2 Issued
2020 Free2Go Trial Published

How can we help?

Choose your path. We'll take it from there.